TG
SWTX

TCW Group’s SpringWorks Therapeutics SWTX Stock Holding History

TCW Group’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-74,671
Closed -$1.84M – 316
2022
Q2 		$1.84M Hold
74,671
– – 0.02% 221
2022
Q1 		$4.21M Buy
74,671
+11
+0% +$629 0.04% 195
2021
Q4 		$4.63M Sell
74,660
-13,454
-15% -$890K 0.04% 208
2021
Q3 		$5.59M Hold
88,114
– – 0.01% 187
2021
Q2 		$7.26M Sell
88,114
-12,054
-12% -$915K 0.06% 174
2021
Q1 		$7.37M Sell
100,168
-22,491
-18% -$1.76M 0.07% 173
2020
Q4 		$8.9M Buy
122,659
+20,861
+20% +$1.34M 0.08% 141
2020
Q3 		$4.85M Sell
101,798
-19,837
-16% -$845K 0.05% 170
2020
Q2 		$5.11M Sell
121,635
-1,123
-0.9% -$40K 0.06% 160
2020
Q1 		$3.31M Buy
+122,758
New +$4M 0.05% 176

Other funds holding SWTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

TCW Group's SWTX Position: Q3 2022 in Review

TCW Group sold out of SpringWorks Therapeutics (SWTX) in Q3 2022, closing a stake of 74,671 shares — an estimated $1.84M sold.

TCW Group first reported a position in SWTX in Q1 2020 and held it in 10 quarters. The position peaked at $8.9M in Q4 2020. 148 funds tracked by Wall St. Rank hold SWTX as of Q3 2022.

  • TCW Group reported no remaining SpringWorks Therapeutics position as of Q3 2022 after selling out during the quarter.
  • TCW Group sold 74,671 SpringWorks Therapeutics shares in Q3 2022, an estimated $1.84M.
  • TCW Group first reported a position in SpringWorks Therapeutics in Q1 2020 and held it in 10 quarters.
  • TCW Group's SpringWorks Therapeutics position peaked at $8.9M in Q4 2020.
  • 148 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2022.

Based on TCW Group's 13F filing for Q3 2022, filed 27 Oct 2022.